Bioherent, a biotechnology startup specialising in the development of in vitro diagnostic devices based on photonic biosensors and nanotechnology, has announced the addition of Axon Partners Group as a new investment partner. Axon will co-invest alongside Bullnet Capital and CDTI-Innvierte, the company’s original investors.
The joint investment from Axon, Bullnet and CDTI will enable Bioherent to advance the clinical validation of its platform for diagnosing antibiotic allergies through highly sensitive, non-invasive methods. It will also support the scaling of manufacturing processes and lay the groundwork for initial commercialisation efforts in Europe.
The addition of Axon provides not only strategic financial backing but also a network of knowledge and expertise essential to Bioherent’s growth,´ said Yara Aceta, CEO of Bioherent. ´Together, we are taking a strong step towards a new paradigm in drug hypersensitivity diagnostics, an area still largely underserved.
This partnership strengthens Bioherent’s commitment to developing accurate, accessible and rapid diagnostic tools that help reduce the overdiagnosis of beta-lactam allergies—one of the contributing factors to the rise in antimicrobial resistance.
We see in Bioherent a distinctive technological proposition, backed by solid science and clear clinical application,´ said Macarena González, Head of Investments in Andalusia at Axon Partners Group. ´We are convinced of this platform’s potential to transform disease diagnostics. With Bioherent, we are helping decentralise access to diagnostics and foster a more personalised, efficient and sustainable approach to healthcare.
